Allurion Technologies (ALUR)
OTHER OTC:ALUR
Want to see ALUR full AI Analyst Report?
ALUR Stock Chart & Stats
$0.80
-$0.76(-9.72%)
At close: 4:00 PM EST
$0.80
-$0.76(-9.72%)
Day’s Range― - ―
52-Week Range$0.23 - $3.33
Previous CloseN/A
Volume63.90K
Average Volume (3M)88.72K
Market Cap
$9.90M
Enterprise Value$28.84M
Total Cash (Recent Filing)$5.06M
Total Debt (Recent Filing)$29.45M
Price to Earnings (P/E)―
Beta2.42
Next Earnings
Aug 19, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.76
Shares Outstanding15,006,253
10 Day Avg. Volume45,410
30 Day Avg. Volume88,723
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-1.20
Price to Sales (P/S)6.09
P/FCF Ratio-3.21
Enterprise Value/Market Cap2.91
Enterprise Value/Revenue2.29
Enterprise Value/Gross Profit4.34
Enterprise Value/Ebitda-0.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$13.70M
Bulls Say, Bears Say
Bulls Say
Cost ManagementOperating expenses of $9.4M were down 48% year over year, as the company continues to closely control spending while prioritizing its growth initiatives.
Sales PerformanceQ3 sales were $2.7M vs the $2.1M Street estimate.
Strategic RealignmentALUR used the quarter to implement the strategy it outlined in August of realigning toward distributors with physician networks that prescribe GLP-1s.
Bears Say
Gross Margin DeclineQ3 gross margin was 49%, down from 58% last year due to the decline in sales and lower production volumes leading to less absorption of labor and overhead costs.
Revenue ShortfallRevenue was $3.4M, which fell short of the $5.2M consensus.
Sales ImpactSales were hurt by the intra-quarter decision to realign toward distributors with physician networks that prescribe GLP-1s.
Allurion Technologies News
ALUR FAQ
What was Allurion Technologies’s price range in the past 12 months?
Allurion Technologies lowest stock price was $0.23 and its highest was $3.33 in the past 12 months.
What is Allurion Technologies’s market cap?
Allurion Technologies’s market cap is $9.90M.
When is Allurion Technologies’s upcoming earnings report date?
Allurion Technologies’s upcoming earnings report date is Aug 19, 2026 which is in 63 days.
How were Allurion Technologies’s earnings last quarter?
Allurion Technologies released its earnings results on May 20, 2026. The company reported -$0.456 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.116.
Is Allurion Technologies overvalued?
According to Wall Street analysts Allurion Technologies’s price is currently Overvalued.
Does Allurion Technologies pay dividends?
Allurion Technologies does not currently pay dividends.
What is Allurion Technologies’s EPS estimate?
Allurion Technologies’s EPS estimate is -0.38.
How many shares outstanding does Allurion Technologies have?
Allurion Technologies has 15,006,253 shares outstanding.
What happened to Allurion Technologies’s price movement after its last earnings report?
Allurion Technologies reported an EPS of -$0.456 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -6.484%.
Which hedge fund is a major shareholder of Allurion Technologies?
Currently, no hedge funds are holding shares in ALUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Allurion Technologies
Allurion Technologies Inc. is dedicated to combating obesity by offering a comprehensive weight management ecosystem designed for individuals with excess weight. At the core of its solution is the Allurion Program, featuring the innovative Allurion Balloon – a novel, non-surgical, swallowable intragastric device engineered to promote significant weight loss. This program is further enhanced by the Allurion Virtual Care Suite, which provides sophisticated AI-powered remote patient monitoring, a specialized behavior modification curriculum, encrypted messaging capabilities, and virtual telehealth consultations. The firm's main operational base is located in Natick, Massachusetts.
Technical Analysis
Ownership Overview
2.18% Insiders
0.24% Mutual Funds
42.81% Other Institutional Investors
54.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---